BioCentury
ARTICLE | Company News

Baxter submits BLA to FDA for hemophilia A product

December 11, 2013 2:45 AM UTC

Baxter International Inc. (NYSE:BAX) submitted a BLA to FDA for OBI-1 to treat acquired hemophilia A. Baxter gained the recombinant porcine Factor VIII earlier this year from Ipsen Group (Euronext:IPN...